Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are used to treat respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. In Nigeria, the market for bronchodilator drugs is developing at a steady pace due to various factors.
Customer preferences: Nigerian consumers are increasingly seeking out bronchodilator drugs due to the rise in respiratory diseases in the country. With air pollution and smoking being major contributors to these diseases, consumers are looking for effective treatments to manage their symptoms. Additionally, the convenience of over-the-counter availability of some bronchodilator drugs is also a factor in customer preference.
Trends in the market: The bronchodilator drugs market in Nigeria is seeing a trend towards increased use of combination therapies. Combination therapies involve using two or more drugs with different mechanisms of action to manage respiratory symptoms. This approach is gaining popularity as it allows for better symptom control and reduces the need for multiple medications.
Local special circumstances: Nigeria has a high prevalence of respiratory diseases, with asthma and COPD being the most common. The country also has a high rate of air pollution, particularly in urban areas, which contributes to the high incidence of respiratory diseases. Additionally, the lack of access to healthcare in some areas of the country means that self-medication is common, leading to increased demand for over-the-counter bronchodilator drugs.
Underlying macroeconomic factors: The Nigerian economy has been growing steadily in recent years, with a focus on healthcare infrastructure and access to medication. This has led to increased availability of bronchodilator drugs in the country, both through government-run healthcare facilities and private pharmacies. However, the cost of these medications can still be a barrier for some consumers, particularly those in rural areas or with low incomes.In conclusion, the bronchodilator drugs market in Nigeria is developing due to a combination of factors such as rising respiratory disease rates, customer preferences for effective treatments, and increased availability of medication. The trend towards combination therapies and the local special circumstances of air pollution and lack of healthcare access are also contributing to the market's growth. However, the cost of medication remains a challenge for some consumers.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
